| Schedule of Earnings Per Share, Basic and Diluted |
The following table presents the calculation of basic and diluted income (loss) per share attributable to common stockholders (in thousands, except share and per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended September 30, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
| Net income (loss), basic and diluted |
$ |
(9,811) |
|
|
$ |
7,662 |
|
|
$ |
(33,747) |
|
|
$ |
(75,032) |
|
| Less: Accretion on redeemable convertible preferred stock |
(976) |
|
|
— |
|
|
(976) |
|
|
— |
|
| Less: Series A accumulated dividends |
(82) |
|
|
$ |
— |
|
|
(82) |
|
|
$ |
— |
|
| Net income (loss) attributable to common stockholders, basic and diluted |
$ |
(10,869) |
|
|
$ |
7,662 |
|
|
$ |
(34,805) |
|
|
$ |
(75,032) |
|
| Net income (loss) per share attributable to common stockholders, basic |
$ |
(0.31) |
|
|
$ |
0.25 |
|
|
$ |
(1.01) |
|
|
$ |
(5.65) |
|
|
|
|
|
|
|
|
|
| Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic |
35,253,756 |
|
30,999,080 |
|
34,433,760 |
|
13,278,710 |
| Effect of dilutive common stock options outstanding |
— |
|
|
2,046,992 |
|
— |
|
|
— |
|
| Effect of dilutive RSUs outstanding |
— |
|
|
110,989 |
|
— |
|
|
— |
|
| Effect of dilutive common stock warrants outstanding |
— |
|
|
63,791 |
|
— |
|
|
— |
|
| Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, diluted |
35,253,756 |
|
33,220,852 |
|
34,433,760 |
|
13,278,710 |
|
|
|
|
|
|
|
|
| Net income (loss) per share attributable to common stockholders, diluted |
$ |
(0.31) |
|
|
$ |
0.23 |
|
|
$ |
(1.01) |
|
|
$ |
(5.65) |
|
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
The following potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
|
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
|
|
|
|
| Redeemable convertible preferred stock |
4,739,336 |
|
|
— |
|
|
4,739,336 |
|
|
— |
|
|
|
|
|
| Common stock options |
1,926,511 |
|
|
1,619,811 |
|
|
1,926,511 |
|
|
4,833,767 |
|
|
|
|
|
| Restricted stock units |
5,161,753 |
|
|
60,728 |
|
|
5,161,753 |
|
|
810,582 |
|
|
|
|
|
| Common stock warrants |
2,598,554 |
|
|
80,740 |
|
|
2,598,554 |
|
|
180,029 |
|
|
|
|
|
| Private and Public Placement Warrants |
2,800,146 |
|
|
2,950,000 |
|
|
2,800,146 |
|
|
2,950,000 |
|
|
|
|
|
| Earn-Out Shares |
2,602,554 |
|
|
2,799,696 |
|
|
2,602,554 |
|
|
2,799,696 |
|
|
|
|
|
| Total |
19,828,854 |
|
|
7,510,975 |
|
|
19,828,854 |
|
|
11,574,074 |
|
|
|
|
|
|